Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Impact of Bone Marrow Fibrosis in Polycythemia Vera
Blood Cancer J; ePub 2017 Mar 10; Barraco, et al
The link between ≥grade 1 bone marrow reticulin fibrosis in polycythemia vera (PV) and later fibrotic progression was confirmed in a study involving 262 individuals.
Investigators sought to validate certain observations in participants with PV, and looked at other risk factors linked with myelofibrosis-free survival (MFFS). Among the results:
Nearly half had ≥grade 1 reticulin fibrosis at diagnosis.
Clinical features were similar in patients with and without bone marrow fibrosis.
Bone marrow fibrosis did not substantially impact overall, leukemia-free, or thrombosis-free survival.
Bone marrow fibrosis was linked with 3-fold higher risk of MFFS.
Other MFFS risk factors included leukocytosis, palpable splenomegaly, and abnormal karyotype.
Barraco D, Cerquozzi S, Hanson C, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: Validation of the IWG-MRT study and additional observations. [Published online ahead of print March 10, 2017]. Blood Cancer J. doi:10.1038/bcj.2017.17.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al